Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Fluence Energy Q2 2026 Earnings Call - Record Backlog and Hyperscaler Wins Drive Order Momentum
Fluence Energy reported a strong second quarter with revenue of $465 million, driven by a record $5.6 billion backlog and accelerating order intake that doubled year-over-year to approximately $2 bill...
- Order intake doubled year-over-year to approximately $2 billion, with a record backlog of $5.6 billion at the end of Q2 2026.
- Second quarter revenue was $465 million, up 8% year-over-year, though $80 million was delayed into Q3 due to logistical issues in Vietnam and Spain.
- Adjusted gross profit margin improved to 11.1% in Q2, within the full-year guidance range of 11%-13%, reflecting disciplined execution.
- +7 more takeaways
Iovance Biotherapeutics Q1 2026 Earnings Call - AMTAGVI Revenue Surges 45% as In-House Manufacturing Drives Margin Expansion and Pipeline Accelerates
Iovance Biotherapeutics delivered a standout first quarter of 2026, with total revenue jumping 45% year-over-year to $71 million, fueled by a 38% surge in AMTAGVI sales to $60 million. The company suc...
- Total first-quarter 2026 revenue reached $71 million, representing a 45% year-over-year increase driven by strong demand for AMTAGVI.
- AMTAGVI revenue grew 38% year-over-year to $60 million, marking the company’s second-highest quarterly revenue for the product.
- Proleukin revenue nearly doubled to $11 million, benefiting from increased adoption alongside AMTAGVI.
- +11 more takeaways
Ring Energy Q1 2026 Earnings Call - Accelerating Capital to Unlock Horizontal Potential Despite Non-Cash Impairments
Ring Energy reported Q1 2026 results that were operationally resilient but heavily weighed down by accounting artifacts. Reported net income was dragged by a $162.1 million ceiling test impairment and...
- 1. Ring Energy is positioning for potential inclusion in the Russell 2000 Index, with the effective date set for late June 2026.
- 2. The company executed a strategic pivot from vertical to horizontal drilling, requiring accelerated infrastructure investments in saltwater disposal and frac water facilities.
- 3. Q1 lease operating expenses came in at $10.41 per BOE, beating the low end of guidance for the fourth consecutive quarter.
- +7 more takeaways
APA Corporation Q1 2026 Earnings Call - Strong Q1 Execution Drives $2.2B FCF Outlook and Accelerates $3B Debt Target
APA Corporation delivered a robust first quarter in 2026, generating $477 million in free cash flow and $489 million in adjusted net income. The company beat production guidance in the Permian and ach...
- APA generated $477 million in free cash flow and $489 million in adjusted net income for Q1 2026, beating expectations and demonstrating strong operational execution across its portfolio.
- The company raised its full-year U.S. oil production outlook to 122,000 barrels per day, driven by improved capital efficiency and uptime in the Permian, while gas volumes were curtailed due to weak Waha pricing.
- In Egypt, adjusted production guidance was lowered due to the impact of higher commodity prices on the Production Sharing Contract (PSC) cost recovery mechanism, though gross production remains strong and base decline rates are moderating.
- +7 more takeaways
Materialise NV Q1 2026 Earnings Call - Portfolio Streamlining Drives Margin Expansion Amid Macro Headwinds
Materialise NV delivered a resilient Q1 2026 with stable EUR 66.3M revenue and sharply improved profitability, driven by disciplined cost management and a strategic shift toward higher-margin medical ...
- Revenue held steady at EUR 66.3 million year-over-year, buffered by foreign exchange headwinds.
- Gross margin expanded to 57.2% from 55.3% in Q1 2025, reflecting operational leverage.
- Adjusted EBIT surged to EUR 2.5 million, up from EUR 0.6 million a year earlier.
- +12 more takeaways
CareCloud Inc Q1 2026 Earnings Call - Capital Structure Simplification and AI Product Scaling Drive Revenue Growth
CareCloud reported Q1 2026 revenue of $31.3 million, up 13% year-over-year, driven by strong recurring revenue growth and accelerating adoption of its AI platform. The company delivered its eighth con...
- Revenue grew 13% to $31.3 million in Q1 2026, with recurring technology-enabled business solution revenue rising to $23 million.
- GAAP net income was $922,000, marking the eighth consecutive quarter of profitability, though lower than prior year due to acquisition-related amortization and integration costs.
- Adjusted EBITDA was $5.4 million (17% of revenue), and adjusted net income was $2.2 million, both essentially in line with the prior year.
- +11 more takeaways
Gold Fields Q1 2026 Earnings Call - Production Up 15% Amid Cost Pressures and Geopolitical Headwinds
Gold Fields delivered a solid Q1 2026 with gold equivalent production up 15% year-over-year to 633,000 ounces, driven by strong recoveries at Salares Norte and higher silver prices. However, all-in su...
- Gold equivalent production rose 15% YoY to 633,000 ounces in Q1 2026, supported by Salares Norte’s improved gold and silver recoveries and favorable silver pricing.
- All-in sustaining costs climbed 13% YoY to $1,829/oz, driven by higher royalties, stronger AUD/ZAR, and input inflation, though management maintains full-year cost guidance.
- A $100/bbl oil price scenario adds ~$50/oz to portfolio costs, but mitigation plans and asset optimizations are expected to keep costs within guidance.
- +11 more takeaways
Ironwood Pharmaceuticals Q1 2026 Earnings Call - LINZESS Sales Surge 97% as Apraglutide Progresses
Ironwood Pharmaceuticals delivered a standout first quarter for LINZESS, with U.S. net sales jumping 97% year-over-year to $272.5 million. The surge was fueled by improved net pricing, driven by the e...
- LINZESS U.S. net sales surged 97% year-over-year to $272.5 million in Q1 2026, driven by improved net pricing rather than demand growth.
- Improved net pricing was primarily due to the elimination of inflationary rebates across channels, including Medicaid, and favorable timing of gross-to-net rebate reserves.
- Prescription demand growth for LINZESS was a modest 5% year-over-year, aligning with management's expectation of low single-digit growth for the full year.
- +7 more takeaways
Park-Ohio Holdings Corp. Q1 2026 Earnings Call - Strong Sales Growth Driven by Data Center and Defense Demand, But Southwest Steel Drag Looms
Park-Ohio Holdings reported a solid first quarter in 2026, with sales rising 4% to $421 million and adjusted EPS of $0.65 beating internal expectations. The growth was broad-based, fueled by surging d...
- Sales grew 4% year-over-year to $421 million, with all three business segments reporting sequential and annual growth.
- Adjusted EPS of $0.65 beat internal expectations, driven by higher segment operating income and a lower effective tax rate of 17%.
- Supply Technologies sales rose 4% to $195 million, with semiconductor and data center demand jumping 13% year-over-year.
- +9 more takeaways
Zoetis Q1 2026 Earnings Call - U.S. Companion Animal Revenue Declines Amid Price Sensitivity and Competitive Pressure
Zoetis reported flat organic operational revenue and 1% growth in adjusted net income for Q1 2026, driven by a sharp divergence between international and U.S. performance. International revenue surged...
- U.S. companion animal revenue declined 8% on an organic operational basis, driven by price-sensitive pet owners, reduced clinic visits, and intensified competition in dermatology and parasiticide franchises.
- International revenue grew 10% organically, led by 12% livestock growth and strong emerging market performance, partially offsetting U.S. softness.
- Apoquel and Simparica franchises faced significant share pressure as competitors launched aggressive pricing strategies and generics encroached on legacy products like Convenia and Cerenia.
- +7 more takeaways